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Introduction {#ijpo12110-sec-0006}
============

The increasing prevalence of overweight and obesity means that non‐alcoholic fatty liver disease (NAFLD), with an estimated prevalence of 20--30%. Rising prevalence rates of NAFLD go hand‐in‐hand with marked increases in obesity prevalence in childhood and adolescence over the past decades [1](#ijpo12110-bib-0001){ref-type="ref"}.

Available epidemiologic data from Europe demonstrates that NAFLD in childhood and adolescence is a problem of global scale [2](#ijpo12110-bib-0002){ref-type="ref"}. In the USA, data from the population‐based National Health and Nutrition Examination Survey III show that approximately 3% of adolescents are affected by elevated alanine aminotransferase (ALT) serum levels [3](#ijpo12110-bib-0003){ref-type="ref"}. In an autopsy study, Schwimmer *et al*. reported an average prevalence of steatosis hepatis of 9.6% in children and adolescents in the USA, which increased with age from 0.7% in the preschool age group to 17.3% in older adolescents [4](#ijpo12110-bib-0004){ref-type="ref"}. Main predictors for NAFLD in childhood and adolescence identified in these studies comprised obesity, older age and male gender. The central role of overweight and obesity as risk factor for paediatric NAFLD is underscored by cohort studies in obese children and adolescents reporting prevalence rates ranging from 10% to 77% [2](#ijpo12110-bib-0002){ref-type="ref"}, [5](#ijpo12110-bib-0005){ref-type="ref"}, [6](#ijpo12110-bib-0006){ref-type="ref"}.

The spectrum of disease ranges from simple steatosis (fatty liver) through nonalcoholic steatohepatitis (NASH) to cirrhosis of the liver. While the prognosis for simple steatosis is favourable, with a benign course, steatohepatitis tends to progress, or may even result in hepatic malignancy [1](#ijpo12110-bib-0001){ref-type="ref"}, [2](#ijpo12110-bib-0002){ref-type="ref"}, [3](#ijpo12110-bib-0003){ref-type="ref"}, [4](#ijpo12110-bib-0004){ref-type="ref"}, [5](#ijpo12110-bib-0005){ref-type="ref"}, [6](#ijpo12110-bib-0006){ref-type="ref"}, [7](#ijpo12110-bib-0007){ref-type="ref"}.

As the development of NAFLD and NASH may play a pivotal role in determining the risk for type 2 diabetes and associated metabolic disease, there has been considerable scientific interest in identifying potential risk factors and surrogate markers for NAFLD in recent years [8](#ijpo12110-bib-0008){ref-type="ref"}. Thyroid hormone status is a key regulator of energy metabolism, while adverse alterations of body composition, lipid status, cardiac function/blood pressure and various non‐traditional cardiovascular risk factors are associated with various degrees of thyroid dysfunction, ranging from subclinical to overt hypothyroidism [9](#ijpo12110-bib-0009){ref-type="ref"}. Elevated levels of thyroid‐stimulating hormone (TSH) are a common finding in populations of obese children and adolescents [10](#ijpo12110-bib-0010){ref-type="ref"}. At present, it remains less clear as to whether the frequently observed hyperthyrotropinemia is a secondary consequence of obesity or whether it has an independent role in the pathogenesis of obesity, dyslipidemia [11](#ijpo12110-bib-0011){ref-type="ref"} and insulin resistance [12](#ijpo12110-bib-0012){ref-type="ref"}. Interestingly, hypothyroidism and NAFLD are characterized by very similar metabolic features, particularly with regard to dyslipidemia, decreased fatty acid oxidation, increased hepatic lipid peroxidation [13](#ijpo12110-bib-0013){ref-type="ref"} and insulin resistance [14](#ijpo12110-bib-0014){ref-type="ref"}. It therefore seems plausible to hypothesize a role for thyroid dysfunction in the pathogenesis of NAFLD [15](#ijpo12110-bib-0015){ref-type="ref"}. A few studies have recently shown a relationship between altered thyroid function test values and NAFLD in both adults [16](#ijpo12110-bib-0016){ref-type="ref"} and children [17](#ijpo12110-bib-0017){ref-type="ref"}, [18](#ijpo12110-bib-0018){ref-type="ref"}.

In a retrospective study of 332 overweight or obese children and adolescents, our aim was to address the hypothesis that there is an association, independent of possible confounders, between thyroid hormone levels and the risk of occurrence and severity (as determined by ultrasound) of NAFLD in obese children and adolescents.

Methods {#ijpo12110-sec-0007}
=======

Study population {#ijpo12110-sec-0008}
----------------

In a prospective cross‐sectional study carried out at the Center for Pediatric and Adolescent Medicine, Department of Internal Medicine I, University of Ulm, and the Hochried Hospital between February 2000 and Mai 2001, data were collected from 617 children and adolescents who were participating in a weight reduction programme at the Hochried Pediatric Medical Center in Murnau. Inclusion criteria for the present study were age between 8 and 20 years, informed consent of the patient or parent or guardian and a fasting period of at least 5 h prior to testing. Exclusion criteria were long‐term medication (including L‐thyroxine, iodide or thyrostatic agents), a history of increased regular alcohol consumption and a lack of lab test results or anthropometric parameters in the database. Out of the total of *n* = 617 children and adolescents in the database, 332 patients were included in the study after applying these criteria. Subjects who had missing data (*n* = 144), invalid laboratory values (*n* = 2), regularly drank alcohol (*n* = 17), were taking regular medication (including thyroid drugs) (*n* = 141) or whose age was outside the defined range (*n* = 30) were excluded. Patients with elevated ALT, aspartate aminotransferase (AST) or gamma‐glutamyltransferase (GGT) levels were screened of hepatitis B, hepatitis C and haemochromatosis. The screening tests were negative in all subjects. The study was approved by the Ethics Committee of the Faculty of Medicine, University of Ulm.

Investigation {#ijpo12110-sec-0009}
-------------

The history of each subject was checked for age, gender, nationality, previous illnesses, regular medication, diets, smoking and alcohol consumption.

Physical data that were extracted included the body weight in kilogrammes (kg) (fasting, wearing only underclothes) and height in centimetres (cm) (standing, without shoes), corrected in each case to one decimal place; blood pressure in millimetres of mercury (mmHg) (three measurements were taken when the patient was sitting down, with the mean calculated from the last two measurements) and abdominal girth in centimetres measured in the horizontal plane at the waist and hips. The values obtained were used to calculate the waist‐to‐hip ratio, body mass index (BMI) and the BMI--standard deviation scores (BMI‐SDS) based on German reference values [19](#ijpo12110-bib-0019){ref-type="ref"} using Cole\'s least mean square (LMS) method [20](#ijpo12110-bib-0020){ref-type="ref"}. The stage of puberty (P1--P5) was determined in accordance with Tanner\'s scale [21](#ijpo12110-bib-0021){ref-type="ref"}, and the subjects were divided into a prepubertal group (Tanner 1), an intrapubertal group (Tanner 2--3) and a postpubertal group (Tanner 4--5).

After a 5‐h fasting period, ultrasound scanning of the liver in three planes was performed by a single experienced examiner (\>50 000 examinations). The subject lay supine with the right arm above the head. Scans were performed in deep inspiration and with a relaxed abdominal wall. A Versa Plus scanner (Siemens, Erlangen, Germany) equipped with a 3.5 MHz multi‐frequency convex array probe was used for the examinations. Venous (20 mL) and capillary (50 μL) blood samples were taken after the subject had not eaten for 12 h. Fasting blood glucose was measured in the capillary sample. An LP 700 analyser was used to determine glucose by GOD‐PAP (glucose oxidase ‐ phenol aminophenazone), cholesterol and high‐density lipoprotein with CHOD‐PAP (cholesterol oxidase ‐ phenol aminophenazone), low‐density lipoprotein from the total cholesterol value as well as cholesterol by a precipitation method and triglycerides with GPO‐PAP (glycerol‐3‐phosphate oxidase ‐ phenol aminophenazone). Insulin was measured with a double‐antibody radioimmunoassay. AST, ALT and GGT were determined with the Dimension RxL system (Dade Behring, Eschborn, Germany) 2using standard methods for transaminases (DuPont, Delaware, USA). The reference ranges were as follows: ALT, 0--23 U L^−1^ (men) and 0--19 U L^−1^ (women); AST, 0--19 U L^−1^ (men) and 0--15 U L^−1^ (women); GGT, up to 14 years of age \<17 U L^−1^ and over 14 years of age \<23 U L^−1^ (men) and \<19 U L^−1^ (women). The thyroid parameters, TSH and triiodothyronine (T3), were assayed with an electrochemiluminescence immunoassay and the E2010 (Roche Diagnostics, Mannheim, Germany). Thyroxine (T4) was measured by the CEDIA T4 test (homogeneous enzyme immunotest) on a Hitachi 917.

Diagnostic criteria {#ijpo12110-sec-0010}
-------------------

The diagnosis of hepatic steatosis was based on the criteria defined by Saverymuttu *et al*. and the severity divided into 'mild' (grade 1), 'moderate' (grade 2) and 'severe' (grade 3) depending on the degree of fatty infiltration [22](#ijpo12110-bib-0022){ref-type="ref"}. Subclinical hypothyroidism was defined as a raised TSH (\>4 μU mL^−1^) and peripheral euthyroidism (T4 normal).

Statistical analysis {#ijpo12110-sec-0011}
--------------------

All statistical analyses were carried out with the statistic software [sas]{.smallcaps} 9.2 (SAS Institute Inc., Cary, North Carolina, USA). First of all, a descriptive evaluation was performed. The mean and standard deviation were calculated for continuous variables and the absolute and relative frequencies for categorical data. To determine differences between the groups with and without NAFLD, the Wilcoxon rank‐sum test was applied for continuous variables and the chi‐squared test for categorical variables, unless the numbers were too small, when Fischer\'s exact test was used. TSH values were divided into four equal groups (quartiles) for the univariate and multivariate analyses. The quartiles were as follows: Q1: TSH ≤ 1.72 μU mL^−1^, Q2: TSH 1.73--2.30 μU mL^−1^, Q3: TSH 2.31--3.22 μU mL^−1^, Q4: TSH ≥ 3.23 μU mL^−1^; Q1: T3 ≤ 1.42 nmol L^−1^, Q2: T3 1.43--1.61 nmol L^−1^, Q3: T3 1.62--1.84 nmol L^−1^, Q4: T3 ≥ 1.85 nmol L^−1^; Q1: T4 ≤ 7.07 nmol L^−1^, Q2: T4 7.08--8.00 nmol L^−1^, Q3: T4 8.01--9.01 nmol L^−1^, Q4: T4 ≥ 9.02 nmol L^−1^. The TSH quartiles were first of all checked by univariate analysis for a relationship with hepatic steatosis. Then, in a multivariate logistic regression analysis, the association between hepatic steatosis and TSH (quartiles) adjusted for age, BMI‐SDS and stage of puberty was examined. In further regression models, the liver function tests (ALT, AST and GGT) and the homeostatic model assessment (HOMA) index were additionally introduced separately into the model, and the relationship between hepatic steatosis and the TSH quartiles investigated after inclusion of the liver function tests and adjustment for age, BMI‐SDS and stage of puberty. All tests were two‐tailed. The level of significance was set at *α* = 5%. The *p*‐value was given to four decimal places, and the odds ratio (OR) and 95% confidence interval were corrected to three decimal places.

Results {#ijpo12110-sec-0012}
=======

Descriptive data analysis {#ijpo12110-sec-0013}
-------------------------

Data from 332 children and adolescents (48.8% male and 51.2% female) were evaluated. The mean age of the population was 14.0 ± 1.8 years, whereby the youngest subject was 10 and the oldest 19. Tanner\'s scores for the stage of puberty revealed 56 prepubertal subjects, 155 subjects in puberty and 121 who were postpubertal. The prepubertal and postpubertal groups showed an unequal gender distribution with more prepubertal boys (*m* = 83.9%; *f* = 16.1%) and postpubertal girls (*m* = 24.0%; *f* = 76.0%). A diagnosis of subclinical hypothyroidism was made in 35 subjects (10.5%). Overt hypothyroidism or hyperthyroidism was not found in any of the subjects.

Hepatic steatosis was demonstrated in 99 (29.8%) subjects (66.7% male and 33.3% female). Depending on the diagnosis, the subjects were divided into two groups, and a comparison was made between those with NAFLD and those without (Table [1](#ijpo12110-tbl-0001){ref-type="table-wrap"}). The NAFLD group had significantly higher values of both BMI‐SDS (*p* \< 0.0001) and waist‐to‐hip ratio (*p* \< 0.0001). Liver function tests results for ALT, AST and GGT (*p* \< 0.0001) were also significantly higher in the NAFLD group than in the subjects without fatty liver changes. The HOMA‐IR (insulin resistance) was also significantly higher (*p* \< 0.0001), as was the systolic blood pressure (*p* = 0.0012) (Table [1](#ijpo12110-tbl-0001){ref-type="table-wrap"}). Taking the thyroid function tests into account, the only significant difference was found for TSH: the mean of 2.8 ± 1.1 mIU L^−1^ in the NAFLD group was significantly higher than the level measured in the control group (*p* = 0.0007). On the other hand, T3 and T4 levels were not significantly different in the two groups. Considering the thyroid function tests in relation to the degree of hepatic steatosis diagnosed on ultrasound, there was a significant rise in TSH with an increasing degree of steatosis (*p* = 0.0027). Such a difference could not be demonstrated for either T3 or T4 (*p* = 0.3475, *p* = 0.6203).

###### 

Characteristics of the study population

  Parameter                    Subjects without NAFLD (*n* = 233) mean ± SD (range)   Subjects with NAFLD (*n* = 99) mean ± SD (range)        Total (*n* = 332)        *p*‐value
  --------------------------- ------------------------------------------------------ -------------------------------------------------- ----------------------------- -----------
  Gender, *n* (%)                                                                                                                                                     
  Male                                              96 (41.2%)                                           66 (66.7%)                              162 (48.8%)           \<0.0001
  Female                                           137 (58.8%)                                           33 (33.3%)                              170 (51.2%)          
  Age (years)                                13.9 ± 1.8 (10.1--19.5)                              14.1 ± 1.9 (10.3--18.3)                  14.0 ± 1.8 (10.1--19.5)      0.4997
  BMI‐SDS                                      2.5 ± 0.5 (1.2--4.6)                                 2.8 ± 0.4 (1.8--3.8)                    2.6 ± 0.5 (1.2--4.6)       \<0.0001
  WHR (m)                                      0.9 ± 0.1 (0.7--2.1)                                 1.0 ± 0.1 (0.8--1.2)                    0.9 ± 0.1 (0.7--2.1)       \<0.0001
  AST (U L^−1^)                               12.7 ± 3.2 (5.1--28.1)                               18.3 ± 8.6 (8.2--64.0)                  14.4 ± 6.0 (5.1--64.0)      \<0.0001
  ALT (U L^−1^)                               11.4 ± 4.2 (6.1--37.5)                              21.3 ± 15.4 (5.4--112.6)                14.3 ± 10.1 (5.4--112.6)     \<0.0001
  GGT (U L^−1^)                               12.3 ± 3.8 (2.2--31.9)                              18.8 ± 11.9 (6.8--86.6)                  14.2 ± 7.8 (2.2--86.6)      \<0.0001
  LDL (mg dL^−1^)                           118.7 ± 32.8 (38.0--225.0)                           125.8 ± 33.0 (47.0--217.0)              120.8 ± 33.0 (38.0--225.0)     0.0751
  HDL (mg dL^−1^)                            46.1 ± 8.9 (26.7--79.7)                              45.0 ± 8.7 (29.1--69.5)                  45.8 ± 8.8 (26.7--79.7)      0.3444
  Cholesterol (mg dL^−1^)                  185.1 ± 32.3 (106.0--289.0)                          195.1 ± 34.8 (115.0--277.0)              188.1 ± 33.3 (106.0--289.0)    0.0179
  Triglycerides (mg dL^−1^)                 98.0 ± 46.2 (20.8--338.0)                            130.1 ± 67.8 (32.1--432.0)              107.6 ± 55.5 (20.8--432.0)    \<0.0001
  Insulin                                     15.1 ± 8.1 (3.2--59.5)                              23.0 ± 14.2 (5.4--64.2)                  17.5 ± 10.9 (3.2--64.2)     \<0.0001
  Leptin                                     31.1 ± 18.9 (1.5--117.4)                             33.7 ± 17.5 (6.3--92.8)                 31.9 ± 18.5 (1.5--117.4)      0.0887
  HOMA                                        3.2 ± 1.9 (0.5--13.2)                                5.1 ± 3.6 (1.1--21.2)                    3.8 ± 2.7 (0.5--21.2)      \<0.0001
  Blood pressure                                                                                                                                                      
  Systolic                                 125.5 ± 12.0 (100.0--160.0)                          129.3 ± 10.9 (105.0--160.0)              126.6 ± 11.8 (100.0--160.0)    0.0012
  Diastolic                                  76.4 ± 8.9 (60.0--115.0)                            78.7 ± 10.6 (60.0--120.0)                77.1 ± 9.5 (60.0--120.0)      0.0577
  T3 (nmol L^−1^)                              1.6 ± 0.3 (0.9--2.8)                                 1.7 ± 0.4 (0.9--2.7)                    1.6 ± 0.3 (0.9--2.8)        0.2380
  T4 (µg dL^−1^)                              8.0 ± 1.4 (4.1--13.3)                                8.0 ± 1.4 (3.7--11.2)                    8.0 ± 1.4 (3.7--13.3)       0.8709
  TSH (μU mL^−1^)                             2.5 ± 1.4 (0.5--11.5)                                 2.8 ± 1.1 (0.7--6.7)                    2.6 ± 1.3 (0.5--11.5)       0.0007

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, gamma‐glutamyltransferase; HDL, high density lipoprotein; HOMA, homeostasis model assessment; LDL, low density lipoprotein; NAFLD, non‐alcoholic fatty liver disease; SD, standard deviation; SDS, standard deviation scores; T3, triiodothyronine; T4, thyroxine; TSH, thyroid‐stimulating hormone; WHR, waist‐to‐hip ratio.

In the in‐depth analysis, the results of the thyroid function tests were subdivided into four equal groups (quartiles), and the corresponding prevalence of NAFLD determined. Here, an increasing prevalence of NAFLD could be seen with increasing TSH values in the first three quartiles (Fig. [1](#ijpo12110-fig-0001){ref-type="fig"}). Univariate analysis showed a significant association of TSH with hepatic steatosis (*p* = 0.0023). After adjustment for age, BMI‐SDS and stage of puberty (prepubertal, intrapubertal and postpubertal), TSH also showed a significant association with hepatic steatosis (*p* = 0.0020). The association of rising TSH levels with hepatic steatosis also remained significant when ALT (*p* = 0.0193) or GGT (*p* = 0.0431) was included in the regression model, but the *p*‐value was just above the level of significance when other lab tests (AST, HOMA index) were included (Table [2](#ijpo12110-tbl-0002){ref-type="table-wrap"}).

![Prevalence of hepatic steatosis in relation to thyroid function in the present study. Q = quartile.](IJPO-12-67-g001){#ijpo12110-fig-0001}

###### 

Logistic regression analysis of the relationship between hepatic steatosis and the TSH quartiles in various models

  Total population (*n* = 332)                                              
  ------------------------------------------------ ------------------------ ------------------
  TSH[\*](#ijpo12110-note-0003){ref-type="fn"}                              
  Q 1                                                     Reference         
  Q 2                                                2.199 (1.010--4.787)   
  Q 3                                                3.850 (1.812--8.181)     **0**.**0023**
  Q 4                                                3.477 (1.631--7.412)   
  TSH[\*\*](#ijpo12110-note-0004){ref-type="fn"}                            
  Q 1                                                     Reference         
  Q 2                                                2.125 (0.956--4.724)   
  Q 3                                                3.431 (1.576--7.470)     **0**.**0020**
  Q 4                                                3.219 (1.474--7.028)   
  TSH[\*\*](#ijpo12110-note-0004){ref-type="fn"}                            
  Q 1                                                     Reference         
  Q 2                                                2.203 (0.907--5.355)   
  Q 3                                                3.372 (1.414--8.041)       **0.0472**
  Q 4                                                2.700 (1.140--6.392)   
  AST                                                                       
  Q 1                                                     Reference         
  Q 2                                                1.266 (0.493--3.255)   
  Q 3                                                2.177 (0.899--5.273)    \<**0**.**0001**
  Q 4                                               10.674 (4.544--25.075)  
  TSH[\*\*](#ijpo12110-note-0004){ref-type="fn"}                            
  Q 1                                                     Reference         
  Q 2                                                2.542 (1.034--6.251)   
  Q 3                                                3.681 (1.532--8.845)     **0**.**0193**
  Q 4                                                3.527 (1.462--8.505)   
  ALT                                                                       
  Q 1                                                     Reference         
  Q 2                                                1.455 (0.528--4.007)   
  Q 3                                                3.626 (1.406--9.353)    \<**0**.**0001**
  Q 4                                               16.392 (6.428--41.800)  
  TSH[\*\*](#ijpo12110-note-0004){ref-type="fn"}                            
  Q 1                                                     Reference         
  Q 2                                                2.167 (0.930--5.051)   
  Q 3                                                3.137 (1.375--7.158)       **0.0431**
  Q 4                                                2.796 (1.212--6.452)   
  GGT                                                                       
  Q 1                                                     Reference         
  Q 2                                                1.489 (0.637--3.484)    \<**0**.**0001**
  Q 3                                                1.535 (0.660--3.568)   
  Q 4                                               7.053 (3.104--16.027)   
  TSH[\*\*](#ijpo12110-note-0004){ref-type="fn"}                            
  Q 1                                                     Reference         
  Q 2                                                1.829 (0.805--4.157)   
  Q 3                                                2.828 (1.270--6.300)       **0.0731**
  Q 4                                                2.349 (1.041--5.303)   
  HOMA index                                                                
  Q 1                                                     Reference         
  Q 2                                                1.393 (0.617--3.142)   
  Q 3                                                1.417 (0.619--3.244)     **0**.**0002**
  Q 4                                               4.788 (2.107--10.884)   

Univariate.

Regression model adjusted for age, BMI‐SDS and stage of puberty.

AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMI, body mass index; CI, confidence interval; GGT, gamma‐glutamyltransferase; HOMA, homeostasis model assessment; OR, odds ratio; WHR, waist‐to‐hip ratio.

Significant values are highlighted in bold.

Discussion {#ijpo12110-sec-0014}
==========

The study presented here shows a significant relationship between increased TSH levels in euthyroid severely obese children and adolescents and the occurrence of hepatic steatosis, independent of age, gender, stage of puberty, BMI‐SDS and other risk markers for NAFLD. Higher TSH levels are associated not only with a higher risk of NAFLD, but also with a greater degree of fatty infiltration found on ultrasound scanning. The results of our study emphasize the possible significance of subclinical hypothyroidism as a predictor of metabolic comorbidity in obese children and adolescents.

Our study has certain limitations. The cross‐sectional design allows the investigation of association, but not causality. Furthermore, the children in our study were not a population‐based paediatric group, but hospital patients. It is therefore not possible to extrapolate our results to the general paediatric population. In addition, the diagnosis of NAFLD was made on the basis of ultrasound scans and not confirmed by histology. However, various studies have shown a high sensitivity (85%) and specificity (94%) for ultrasound in the diagnostic investigation of hepatic steatosis [23](#ijpo12110-bib-0023){ref-type="ref"}. A good correlation between the steatosis score determined on ultrasound and the histological grade of steatosis is also found in children [24](#ijpo12110-bib-0024){ref-type="ref"}.

Thyroid hormone status has a considerable effect on energy metabolism as well as on the cardiovascular system. Patients with overt hypothyroidism have unfavourable changes in the classical cardiovascular risk factors, in particular, clearly elevated total cholesterol and low‐density lipoprotein cholesterol levels [25](#ijpo12110-bib-0025){ref-type="ref"}. The possible relationship between subclinical hypothyroidism and increased cardiovascular morbidity and mortality is still a controversial subject of debate. However, recent meta‐analyses of epidemiological studies provide evidence that subclinical hypothyroidism in adult patients is associated with an increased risk of coronary heart disease and increased mortality [9](#ijpo12110-bib-0009){ref-type="ref"}. In contrast, there is little data on a possible relationship between subclinical hypothyroidism and NAFLD, although it would seem likely, because patients with overt hypothyroidism often have fatty infiltration of the liver [15](#ijpo12110-bib-0015){ref-type="ref"}. Metabolic changes in hypothyroidism have clear similarities with key metabolic features of NAFLD or NASH, namely, reduced beta‐oxidation of fatty acids, increased peroxidation of lipids, which is an important source of oxidative stress in liver tissue and a cause of cellular injury [13](#ijpo12110-bib-0013){ref-type="ref"} and, in particular, insulin resistance [14](#ijpo12110-bib-0014){ref-type="ref"}. Furthermore, alterations in leptin‐signalling or FGF‐21‐signalling pathways may provide pathophysiological linkage of hypothyroidism and NAFLD (reviewed in [26](#ijpo12110-bib-0026){ref-type="ref"}). For example, increased levels of leptin have been observed in hypothyroidism, which may promote hepatic insulin resistance and also hepatic collagen synthesis [27](#ijpo12110-bib-0027){ref-type="ref"}.

In a large‐scale study on more than 10 000 adult Caucasian patients, Targher *et al*. showed a progressive increase in AST, ALT and GGT with rising TSH levels, independent of age, gender, lipid status and fasting glucose [28](#ijpo12110-bib-0028){ref-type="ref"}. A Chinese study on similarly large population of adult patients came to contradictory conclusions [16](#ijpo12110-bib-0016){ref-type="ref"}. In their cross‐sectional study, however, Chung *et al*. investigated 4648 subjects, of whom 2324 were euthyroid and 2324 had hypothyroidism. They showed here an association between hepatic steatosis and hypothyroidism or TSH levels [16](#ijpo12110-bib-0016){ref-type="ref"}.

To our knowledge, there are currently only three studies that have looked at a possible relationship between thyroid dysfunction and NAFLD in children and adolescents [17](#ijpo12110-bib-0017){ref-type="ref"}, [18](#ijpo12110-bib-0018){ref-type="ref"}, [29](#ijpo12110-bib-0029){ref-type="ref"}. A cross‐sectional study by Torun *et al*. with 109 obese subjects aged between 9 and 15 years showed a significant correlation of rising TSH levels with an increasing degree of hepatic steatosis, as determined on ultrasound scanning [18](#ijpo12110-bib-0018){ref-type="ref"}.

The present study confirms the findings of Torun *et al*. [18](#ijpo12110-bib-0018){ref-type="ref"} in a large‐scale, well‐characterized population of central European children and adolescents and also shows the association between rising TSH levels and the ultrasound grade of fatty liver to be independent of possible confounders. It must be emphasized that the association of TSH with the severity of fatty liver described in our study can be demonstrated in children and adolescents who are euthyroid with respect to T3 and T4 as well as in those who are euthyroid to TSH. In addition, there was no change in the T3/T4 ratio in our study, unlike that found in other smaller studies on obese children and adolescents with NAFLD [29](#ijpo12110-bib-0029){ref-type="ref"}.

In a study population of 402 overweight or obese children and adolescents aged between 6 and 16 years, Pacifico *et al*. showed that an elevated TSH \>4 mIU L^−1^ with euthyroid metabolism is associated with hepatic steatosis, giving significantly higher ORs of 2.10 without raised ALT levels and of 2.42 when ALT was also raised [17](#ijpo12110-bib-0017){ref-type="ref"}. Using the same arbitrary cut‐off for TSH (\>4 mIU L^−1^) as in Pacifico\'s study and adjusting for the same possible confounders, the OR for the presence of steatosis was not statistically significant in our study population (data not shown). One possible reason for this finding may be the different distribution of the TSH levels and the different number of subjects with TSH \> 4 mIU L^−1^ in the two study populations. Only 10.2% of the children and adolescents in our study had TSH levels above 4 mIU L^−1^, while twice as many had TSH levels \> 4 mIU L^−1^ in the study by Pacifico *et al*. As our results clearly show, the relationship between rising TSH levels and the probability/odds of having hepatic steatosis seems to be effective not only on the threshold or outside the normal age‐related range, but even more so already within the normal range for TSH (and T3 and T4). Obese children and adolescents with a TSH level of 1.73--2.30 μU mL^−1^ (in Q2) have twice the probability of hepatic steatosis than children with peripheral euthyroidism and a TSH level ≤ 1.72 μU mL^−1^ (Q1). Adjusted for age, stage of puberty and BMI‐SDS, the probability of hepatic steatosis again increases when the TSH level reaches the next quartile (TSH 2.31--3.22 μU mL^−1^) but does not increase any further. This finding suggests that discreet elevations of TSH could be a previously overlooked sign of NAFLD and supports the idea that subclinical disorders of thyroid function are also associated with an unfavourable metabolic risk profile in children and adolescents [11](#ijpo12110-bib-0011){ref-type="ref"}.

As the pathogenesis of NAFLD is not yet completely understood [1](#ijpo12110-bib-0001){ref-type="ref"} and the disease is associated with increased morbidity and mortality in children as well as adults [30](#ijpo12110-bib-0030){ref-type="ref"}, the identification of other relevant factors is extremely important to allow causal treatment and prevent sequelae. Given the current database, the lack of comparability between studies and the differences in methodology, further large‐scale studies are needed to evaluate TSH as an independent risk factor for NAFLD.
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